Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
1 file | 3.18 MB
Add to list
  1. Search results
  2. Can dendritic cells improve whole can...

Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?

Laetitia Cicchelero (UGent) , Sofie Denies (UGent) , Bert Devriendt (UGent) , Hilde De Rooster (UGent) and Niek Sanders (UGent)
(2015) ONCOIMMUNOLOGY. 4(12).
Author
Organization
Abstract
Immunogenic cell death (ICD) offers interesting opportunities in cancer cell (CC) vaccine manufacture, as it increases the immunogenicity of the dead CC. Furthermore, fusion of CCs with dendritic cells (DCs) is considered a superior method for generating whole CC vaccines. Therefore, in this work, we determined in naive mice whether immunogenically killed CCs per se (CC vaccine) elicit an antitumoral immune response different from the response observed when immunogenically killed CCs are associated with DCs through fusion (fusion vaccine) or through co-incubation (co-incubation vaccine). After tumor inoculation, the type of immune response in the prophylactically vaccinated mice differed between the groups. In more detail, fusion vaccines elicited a humoral anticancer response, whereas the co-incubation and CC vaccine mainly induced a cellular response. Despite these differences, all three approaches offered a prophylactic protection against tumor development in the murine mammary carcinoma model. In summary, it can be concluded that whole CC vaccines based on immunogenically killed CCs may not necessarily require association with DCs to elicit a protective anticancer immune response. If this finding can be endorsed in other cancer models, the manufacture of CC vaccines would greatly benefit from this new insight, as production of DC-based vaccines is laborious, time-consuming and expensive.
Keywords
whole cancer cell vaccine, cancer immunotherapy, fusion, immunogenic cell death, co-incubation, REGULATORY T-CELLS, FUSION VACCINE, GENE-THERAPY, TUMOR-CELLS, BONE-MARROW, IMMUNOTHERAPY, CARCINOMA, MELANOMA, EFFICACY, DEATH

Downloads

  • Download
    (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 3.18 MB

Citation

Please use this url to cite or link to this publication:

MLA
Cicchelero, Laetitia, et al. “Can Dendritic Cells Improve Whole Cancer Cell Vaccines Based on Immunogenically Killed Cancer Cells?” ONCOIMMUNOLOGY, vol. 4, no. 12, 2015, doi:10.1080/2162402X.2015.1048413.
APA
Cicchelero, L., Denies, S., Devriendt, B., De Rooster, H., & Sanders, N. (2015). Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells? ONCOIMMUNOLOGY, 4(12). https://doi.org/10.1080/2162402X.2015.1048413
Chicago author-date
Cicchelero, Laetitia, Sofie Denies, Bert Devriendt, Hilde De Rooster, and Niek Sanders. 2015. “Can Dendritic Cells Improve Whole Cancer Cell Vaccines Based on Immunogenically Killed Cancer Cells?” ONCOIMMUNOLOGY 4 (12). https://doi.org/10.1080/2162402X.2015.1048413.
Chicago author-date (all authors)
Cicchelero, Laetitia, Sofie Denies, Bert Devriendt, Hilde De Rooster, and Niek Sanders. 2015. “Can Dendritic Cells Improve Whole Cancer Cell Vaccines Based on Immunogenically Killed Cancer Cells?” ONCOIMMUNOLOGY 4 (12). doi:10.1080/2162402X.2015.1048413.
Vancouver
1.
Cicchelero L, Denies S, Devriendt B, De Rooster H, Sanders N. Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells? ONCOIMMUNOLOGY. 2015;4(12).
IEEE
[1]
L. Cicchelero, S. Denies, B. Devriendt, H. De Rooster, and N. Sanders, “Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?,” ONCOIMMUNOLOGY, vol. 4, no. 12, 2015.
@article{6851345,
  abstract     = {{Immunogenic cell death (ICD) offers interesting opportunities in cancer cell (CC) vaccine manufacture, as it increases the immunogenicity of the dead CC. Furthermore, fusion of CCs with dendritic cells (DCs) is considered a superior method for generating whole CC vaccines. Therefore, in this work, we determined in naive mice whether immunogenically killed CCs per se (CC vaccine) elicit an antitumoral immune response different from the response observed when immunogenically killed CCs are associated with DCs through fusion (fusion vaccine) or through co-incubation (co-incubation vaccine). After tumor inoculation, the type of immune response in the prophylactically vaccinated mice differed between the groups. In more detail, fusion vaccines elicited a humoral anticancer response, whereas the co-incubation and CC vaccine mainly induced a cellular response. Despite these differences, all three approaches offered a prophylactic protection against tumor development in the murine mammary carcinoma model. 
In summary, it can be concluded that whole CC vaccines based on immunogenically killed CCs may not necessarily require association with DCs to elicit a protective anticancer immune response. If this finding can be endorsed in other cancer models, the manufacture of CC vaccines would greatly benefit from this new insight, as production of DC-based vaccines is laborious, time-consuming and expensive.}},
  articleno    = {{e1048413}},
  author       = {{Cicchelero, Laetitia and Denies, Sofie and Devriendt, Bert and De Rooster, Hilde and Sanders, Niek}},
  issn         = {{2162-402X}},
  journal      = {{ONCOIMMUNOLOGY}},
  keywords     = {{whole cancer cell vaccine,cancer immunotherapy,fusion,immunogenic cell death,co-incubation,REGULATORY T-CELLS,FUSION VACCINE,GENE-THERAPY,TUMOR-CELLS,BONE-MARROW,IMMUNOTHERAPY,CARCINOMA,MELANOMA,EFFICACY,DEATH}},
  language     = {{eng}},
  number       = {{12}},
  pages        = {{9}},
  title        = {{Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?}},
  url          = {{http://doi.org/10.1080/2162402X.2015.1048413}},
  volume       = {{4}},
  year         = {{2015}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: